超全视网膜光凝联合玻璃体腔注射康柏西普治疗新生血管性青光眼  

Treatment of intravitreal injection of Conbercept with extra-panretinal photocoagulation for neovascular glaucoma

作　　者：刘修铎[1] 徐惠娣 孙钰[1] 王倩[1] 陆璐[1] 陈志斌[1] 赵婕[1] 

机构地区：[1]中国上海市杨浦区市东医院眼科,200438

出　　处：《国际眼科杂志》2017年第1期140-142,共3页International Eye Science

摘　　要：目的:观察玻璃体腔注射康柏西普联合超全视网膜光凝(extra-panretinal photocoagulation,E-PRP)治疗新生血管性青光眼的临床疗效。方法:回顾总结2015-01/12我院住院和门诊就诊的视网膜中央静脉阻塞(central retinal vein obstruction,CRVO)继发性青光眼16例16眼患者,行玻璃体腔注射康柏西普1.0mg,再联合E-PRP。观察治疗前后眼压、视力、新生血管消退情况及并发症出现情况。结果:末次随访16眼,虹膜及房角新生血管全部消退。治疗前眼压42~65(平均50.85±6.97)mmH g,治疗后平均眼压在各观察节点均有显著下降,治疗前后眼压相比较有统计学差异(P<0.05)。末次随访时视力与术前相比不变者12眼,提高2行以上者2眼,下降2行以上者2眼,末次随访时视力与术前相比无统计学差异(P>0.05)。未发生眼内炎、视网膜脱离等严重并发症。结论:玻璃体腔注射康柏西普联合超全视网膜光凝治疗新生血管性青光眼疗效可靠。AIM： To investigate the clinical efficacy of intravitreal injection of Conbercept combined with extra-panretinal photocoagulation for neovascular glaucoma（NVG）. METHODS： Sixteen eyes of 16 NVG patients in our hospital were treated with intravitreal injection of conbercept 1.0mg, combined with extra-panretinal photocoagulation. Changes of visual acuity, intraocular pressure（IOP）, iris neovascular vessels and complications were observed before and after operation.RESULTS： At the final follow-up, iris neovascular vessels disappeared in all patients. There was statistically significant difference on IOP between before and after operation（P〈0.05）. The visual acuity was improved in 2 eyes, was stable in 12 eyes and was decreased in 2 eyes. There was no statistically significant difference on visual acuity between before and after operation（P〉0.05）. There were no entophthalmia, retinal detachment and other serious complications after our operation. CONCLUSION： Intravitreal injection of conbercept combined with extra-panretinal photocoagulation is effective for neovascular glaucoma.

关 键 词：超全视网膜光凝术 玻璃体腔注射 康柏西普 新生血管性青光眼 

分 类 号：R779.6[医药卫生—眼科]